Nephronophthisis 18 (NPHP18) Cell Models for Research

Nephronophthisis 18 (NPHP18) is a rare autosomal recessive ciliopathy caused by mutations in the CEP83 gene. It is a subtype of nephronophthisis, a leading genetic cause of end-stage renal disease (ESRD) in children and young adults. The exact prevalence is unknown, but nephronophthisis collectively affects approximately 1 in 50,000 individuals worldwide (WHO). NPHP18 typically presents with polyuria, polydipsia, and progressive renal failure, often leading to ESRD within the first two decades of life. There is no cure, and treatment is supportive, including dialysis and transplantation. The disease is characterized by cystic kidney disease and extrarenal manifestations such as retinal degeneration and cerebellar vermis hypoplasia (Joubert syndrome). Research is crucial to understand the molecular mechanisms and develop targeted therapies.

NPHP18 is an ideal model for studying ciliary function and renal fibrosis. The CEP83 gene encodes a component of the distal appendages of centrioles, essential for ciliogenesis. Mutations lead to defective primary cilia, which are critical for cellular signaling. The disease has a clear genotype-phenotype correlation, and patient-derived cell lines and animal models are available. Public datasets, such as those from NCBI and ClinVar, provide mutation information. Open questions include the precise role of CEP83 in ciliary signaling and the development of therapeutic strategies to slow disease progression.

• • Although NPHP18 is not a cancer, it shares pathways with cancer biology, particularly those involving cilia and cell signaling. The primary pathways affected include:
• • Ciliary signaling pathways: Defective cilia impair Hedgehog (Hh) and Wnt signaling, which are crucial for tissue development and homeostasis.
• • Planar cell polarity (PCP) pathway: Disrupted ciliary function affects PCP, leading to tubular dilation and cyst formation.
• • Mechanosensing: Primary cilia act as mechanosensors; their dysfunction alters intracellular calcium signaling and gene expression.
• • Inflammatory and fibrotic pathways: Chronic kidney injury triggers TGF-β and NF-κB signaling, promoting fibrosis.

Data from ClinVar and NCBI Gene. Note: NPHP18 is specifically caused by CEP83 mutations.

• • The primary cilia are signaling hubs. In NPHP18, the following networks are deregulated:
• • Hedgehog (Hh) signaling: Cilia are required for Hh signal transduction. Loss of CEP83 leads to reduced Gli transcription factor activity.
• • Wnt signaling: Both canonical (β-catenin-dependent) and non-canonical (PCP) pathways are affected, leading to altered cell proliferation and polarity.
• • TGF-β signaling: Upregulated in response to injury, promoting epithelial-to-mesenchymal transition (EMT) and fibrosis.
• • Calcium signaling: Ciliary mechanosensation is impaired, leading to altered intracellular calcium levels and downstream gene expression.

Organoids derived from patient iPSCs recapitulate cystic kidney phenotypes and are useful for drug screening.

• • CEP83 knockout mouse: Exhibits renal cystic disease and embryonic lethality, used to study ciliary function.
• • Conditional knockout mouse: Tissue-specific deletion of CEP83 in renal tubules to model progressive disease.
• • Zebrafish models: cep83 morpholino knockdown shows pronephric cysts, suitable for high-throughput screening.
• • Patient-derived xenografts (PDX) are not applicable for non-cancer diseases, but kidney organoids can be transplanted into mice for in vivo studies.

• • CRISPR-Cas9 technology enables the generation of isogenic cell lines with precise CEP83 mutations. For example:
• • CEP83 knockout cell lines: Complete loss of function, mimicking severe mutations.
• • CEP83 knock-in cell lines: Introduction of patient-specific point mutations (e.g., p.Arg123Ter) to study genotype-phenotype correlations.
• • Reporter cell lines: Cilia-specific reporters (e.g., Arl13b-GFP) to visualize cilia in live cells.

These sequence-verified models are commercially available and accelerate research by providing consistent, reproducible systems. They are essential for drug screening and functional studies.

• • Gene-edited cell lines allow functional validation of CEP83 variants. For example:
• • Knockout lines confirm the role of CEP83 in ciliogenesis by showing loss of primary cilia.
• • Knock-in lines with specific mutations enable assessment of protein function and localization.
• • CRISPR screens can identify genetic modifiers that rescue ciliary defects, providing novel therapeutic targets.

Isogenic pairs (wild-type vs. CEP83 knockout) are used to screen for compounds that restore ciliogenesis or reduce cyst formation. High-content imaging assays measure cilia length and number. Resistance can be modeled by exposing cells to drugs and selecting for resistant clones, which may acquire secondary mutations.

CRISPR synthetic lethality screens can identify genes that are essential only in CEP83-deficient cells, revealing potential biomarkers and therapeutic targets. For example, targeting such genes may selectively kill diseased cells while sparing normal cells.